UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________ FORM 10-Q _______________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 ____________________ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 CORCEPT THERAPEUTICS INCORPORATED (Exact Name of Corporation as Specified in Its Charter) Delaware 77-0487658 (State or other jurisdictio ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) Q4 2020 Earnings Conference Call February 8, 2021 5:00 PM ET Company Participants Charlie Robb - Chief Financial Officer Joseph Belanoff - Chief Executive Officer Sean Maduck - Chief Commercial Officer Andreas Grauer - Chief Medical Officer Conference Call Participants Tazeen Ahmad - Bank of America Chris Howerton - Jefferies Swayampakula Ramakanth - H.C. Wainwright Matt Kaplan - Ladenburg Thalmann Alan Leong - BioWatch News Operator Ladies and gentlemen, than ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) Q3 2020 Earnings Conference Call November 3, 2020 5:00 PM ET Company Participants Charlie Robb - Chief Financial Officer Joseph Belanoff - Chief Executive Officer Conference Call Participants Tazeen Ahmad - Bank of America Matt Kaplan - Ladenburg Thalmann Roger Song - Jefferies Swayampakula Ramakanth - H.C. Wainwright Alan Leong - BioWatch News Operator Good day, and welcome to the Corcept Therapeutics Conference Call. Today's call is being recorded. [Operator ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________ FORM 10-Q _______________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 ________________ ...

Corcept Therapeutics, Inc. (NASDAQ:CORT) Q1 2020 Earnings Conference Call August 4, 2020 5:00 PM ET Company Participants Charlie Robb – Chief Financial Officer Joseph Belanoff – Chief Executive Officer Conference Call Participants Chris Howerton – Jefferies Matt Kaplan – Ladenburg Thalmann Swayampakula Ramakanth – H.C. Wainwright Alan Leong – BioWatch News Operator Good day, and welcome to the Corcept Therapeutics Conference Call. Today’s conference is being recorded. [Operator Instructions] At this time, I ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________ FORM 10-Q _______________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 _____________________ ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2020 Earnings Conference Call May 4, 2020 5:00 PM ET Company Participants Joseph Belanoff - President and Chief Executive Officer Charlie Robb - Chief Financial Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Tazeen Ahmad - Bank of America Matt Kaplan - Ladenburg Thalmann Chris Howerton - Jefferies Swayampakula Ramakanth - H.C. Wainwrigh Alan Leong - BioWatch News Operator Good day, everyone and welcome to the Corcept Therapeutics Co ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________ FORM 10-Q _______________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 ____________________ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 CORCEPT THERAPEUTICS INCORPORATED (Exact Name of Corporation as Specified in Its Charter) Delaware 77-0487658 (State or other jurisdictio ...